954-P: GLP-1–Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting (EXPERT Study)

Abstract

Introduction: The effect of once-weekly (OW) subcutaneous semaglutide, a glucagon-like peptide-1 (GLP-1) analog for the treatment of T2D, has been examined in GLP-1-naïve patients only. Here, we examined glycemic control and weight management in GLP-1-experienced patients switching from another GLP-1 to semaglutide in a real-world setting, using U.S. prescription data. Methods: Adults (≥18 years old) with T2D were identified in the Explorys (IBM Watson Health) U.S. electronic medical records database (data cut-off 12/5/19). Included patients had ≥1 prescription for semaglutide (index/switch date), a prescription for any other GLP-1 (baseline) in the previous year, and separate HbA1c/weight measurements at 6 or 12 months post-index and in the 90-day pre-index period. Results: Patients with valid HbA1c (N=365) and weight (N=480) data had similar baseline characteristics. Both the full 6-month cohorts and subgroups with 12-month data had significant HbA1c and weight reductions (Figure). Significant HbA1c improvement at 6 months was sustained at 12 months, whereas weight loss was more pronounced with longer follow-up. HbA1c and weight changes were independent of previous GLP-1 used (p>0.05 between GLP-1s). Conclusions: Switching to OW semaglutide from another GLP-1 was associated with significant HbA1c and weight reductions in routine clinical practice, independent of previous GLP-1 used. Disclosure I. Lingvay: Consultant; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Intarcia Therapeutics, Janssen Pharmaceuticals, Inc., MannKind Corporation, Novo Nordisk A/S, Sanofi, TARGET PharmaSolutions, Valeritas, Inc. Other Relationship; Self; Novo Nordisk A/S. A. Kirk: Employee; Self; Novo Nordisk A/S. Stock/Shareholder; Self; Novo Nordisk A/S. S. Lophaven: Consultant; Self; Novo Nordisk A/S. M.L. Wolden: Employee; Self; Novo Nordisk A/S. Stock/Shareholder; Self; Novo Nordisk A/S. J.H. Shubrook: Advisory Panel; Self; Bayer U.S., Eli Lilly and Company, Novo Nordisk Inc., Sanofi US. Funding Novo Nordisk A/S